Nuvalent
NUVL | NASDAQ
$123.96
$0.00 (0.00%)
At close: Jul 14, 2026, 4:00 PM ET
Nuvalent Company Profile
Company profile explainedCompany Profile
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Key Executives
| Name | Position |
|---|---|
| James R. Porter | Chief Executive Officer, President & Director |
| Alex Balcom | Chief Financial Officer & Treasurer |
| Deborah Ann Miller | Chief Legal Officer & Secretary |
| Benjamin Lane | Chief Technical Operations Officer |
| Chelcie Lister | Senior Director of Investor Relations & Corporate Communications |
| Christopher D. Turner | Chief Medical Officer |
| Darlene Noci | Chief Development Officer |
| Henry Pelish | Chief Scientific Officer |
| John Soglia | Senior Vice President of Translational Development |
| Joshua Horan | Senior Vice President of Chemistry |
| Ruth Adams | Senior Vice President of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 27, 2026 | 15-12G | Filing |
| Jul 17, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 17, 2026 | 4 | Filing |
| Jul 15, 2026 | 4 | Filing |
| Jul 15, 2026 | 4 | Filing |
| Jul 15, 2026 | 4 | Filing |
| Jul 15, 2026 | 4 | Filing |
| Jul 15, 2026 | 4 | Filing |
| Jul 15, 2026 | 4 | Filing |
| Jul 15, 2026 | 4 | Filing |
Nuvalent
| Country | United States |
| IPO Date | Jul 29, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 234 |
| CEO | James R. Porter |
Contact Details
One Broadway Cambridge,
Massachusetts 02142 United States
Stock Details
| Ticker Symbol | NUVL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001861560 |
| CUSIP Number | 670703107 |
| ISIN Number | US6707031075 |
| SIC Code | 2834 |
Recent News
- 5 months ago / globenewswire.comBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE - TMHC),
- 5 months ago / globenewswire.comNUVL Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of Nuvalent to GSK
- 5 months ago / globenewswire.comHalper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders
- 5 months ago / benzinga.comJM Smucker, Nuvalent, FuelCell Energy And Other Big Stocks Moving Higher On Tuesday
- 5 months ago / investors.comNuvalent Catapults To Record High On GSK's $10.6 Billion All-Cash Bid
- 5 months ago / schaeffersresearch.comNuvalent Stock Soars on $10.6 Billion GSK Buyout
- 5 months ago / businesswire.comNUVL Stock Alert: Halper Sadeh LLC is Investigating Whether Nuvalent, Inc. is Obtaining a Fair Price for its Shareholders
- 5 months ago / proactiveinvestors.comGSK falls as £8bn takeover of Nuvalent is largest deal in a decade
- 6 months ago / prnewswire.comNuvalent Announces Key Program and Business Updates, Strengthening Foundation for Global Leadership in ROS1- and ALK-positive NSCLC
- 6 months ago / prnewswire.comNuvalent Highlights Upcoming Data Presentations for Neladalkib and Zidesamtinib at the 2026 American Society of Clinical Oncology Annual Meeting
Add to Watchlist
Select watchlists to add or remove NUVL